A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, aimed at improving access to quality medical ...

Coya Therapeutics raised $11.1 million to support manufacturing scale-up for its experimental ALS therapy, COYA 302.

According to the ALS Association, most patients of the disease die within five years of diagnosis. Reporting for TODAY, NBC’s Anne Thompson shares a look at a groundbreaking therapy called an ASO that ...

On a quiet farm in Erie County, Pennsylvania, 67-year-old Diane Zaczyk used to think nothing of hefting 50-pound sacks of chicken feed onto her shoulder. Strong, stubborn and devoted to caring for her ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

Six newly Certified Centers join the organization's network of clinics and expand access to multidisciplinary care and research for people living with ALS. ALS, often called Lou Gehrig's disease, is a ...

A pharmaceutical company based in New Jersey that’s known for its FDA-approved treatment for ALS is set to be acquired for $2.5 billion. Tanabe Pharma America, which operates a U.S. headquarters in ...

Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has ...

The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves ...